PCVX vs QGEN: stock comparison and AI forecast
Vaxcyte, Inc. (PCVX) and Qiagen N.V. (QGEN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
PCVX Vaxcyte, Inc.
- Market Cap
- $9.02B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
QGEN Qiagen N.V.
- Price
- $50.35 +48.3% · 6M
- Market Cap
- $10.92B
- P/E Ratio
- 35.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- QGEN is 1.2 times larger than PCVX by market capitalization ($10.92B against $9.02B).
- QGEN carries 0.66 times debt per unit of equity, against 0.14 times for PCVX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | PCVX | QGEN |
|---|---|---|
| Market Cap | $9.02B | $10.92B |
| P/E Ratio | – | 35.71x |
| P/B Ratio | 3.27x | 2.89x |
| EPS | $-7.64 | $1.41 |
| Book Value/Share | $18.53 | $17.42 |
| FCF/Share | $-6.01 | – |
Profitability & Margins
| Metric | PCVX | QGEN |
|---|---|---|
| ROE | -38.6% | 8.4% |
| ROA | -33.9% | 5.1% |
| ROIC | -40.6% | 6.5% |
| Gross Margin | – | 59.8% |
| Operating Margin | – | 18.4% |
| Net Margin | – | 15.6% |
| EBT Margin | – | 19.0% |
| Tax Rate | 0.0% | 18.1% |
Financial Health
| Metric | PCVX | QGEN |
|---|---|---|
| Current Ratio | 5.72x | 3.90x |
| Quick Ratio | – | 3.31x |
| D/E Ratio | 0.14x | 0.66x |
| Financial Leverage | 1.14x | 1.66x |
| Interest Coverage | -3390.0x | 15.9x |
| Working Capital | $1.28B | $1.48B |
Cash Flow
| Metric | PCVX | QGEN |
|---|---|---|
| Operating Cash Flow | -$881M | $626M |
| Free Cash Flow | -$894M | – |
| Capital Spending | -$13M | – |
| OCF Growth YoY | – | 40.0% |
Operational Efficiency
| Metric | PCVX | QGEN |
|---|---|---|
| Inventory Turnover | – | 2.7x |
| Days Inventory | – | 134 days |
| Payables Period | – | 32 days |
Income Statement
| Metric | PCVX | QGEN |
|---|---|---|
| Operating Income | -$1.17B | $376M |
| Net Income | -$1.06B | $318M |
| R&D Expense | $1.03B | $192M |
| SG&A Expense | – | $678M |
| Cost of Goods Sold | – | $822M |
Dividend & Shareholder Information
| Metric | PCVX | QGEN |
|---|---|---|
| Shares Outstanding | 149M | 217M |
| EPS Growth | – | 28.5% |
PCVX vs QGEN: stock comparison and AI forecast
Which is bigger, PCVX or QGEN?
QGEN is 1.2 times larger than PCVX by market capitalization ($10.92B against $9.02B).
Which one does Intratio's AI model rank higher, PCVX or QGEN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.